INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $280,921 | -13.3% | 5,393 | +5.4% | 0.02% | -6.2% |
| Q2 2023 | $323,945 | +21.1% | 5,116 | +3.5% | 0.02% | +14.3% |
| Q1 2023 | $267,555 | -12.0% | 4,941 | -14.0% | 0.01% | 0.0% |
| Q4 2022 | $304,025 | +18.3% | 5,745 | +4.0% | 0.01% | +7.7% |
| Q3 2022 | $256,939 | -18.5% | 5,522 | 0.0% | 0.01% | -7.1% |
| Q2 2022 | $315,196 | +0.3% | 5,522 | +7.6% | 0.01% | +27.3% |
| Q1 2022 | $314,149 | -67.3% | 5,134 | -72.0% | 0.01% | -15.4% |
| Q4 2021 | $961,067 | +31.4% | 18,362 | -6.4% | 0.01% | +18.2% |
| Q3 2021 | $731,508 | -8.2% | 19,622 | +0.5% | 0.01% | 0.0% |
| Q2 2021 | $797,092 | +28.0% | 19,527 | +6.4% | 0.01% | +22.2% |
| Q1 2021 | $622,514 | +2.7% | 18,347 | -3.8% | 0.01% | 0.0% |
| Q4 2020 | $606,172 | +23.9% | 19,062 | 0.0% | 0.01% | 0.0% |
| Q3 2020 | $489,131 | +15.8% | 19,062 | +15.9% | 0.01% | +28.6% |
| Q2 2020 | $422,323 | +67.0% | 16,452 | 0.0% | 0.01% | +40.0% |
| Q1 2020 | $252,867 | -42.7% | 16,452 | +27.9% | 0.01% | -28.6% |
| Q4 2019 | $441,467 | +321.6% | 12,867 | -8.2% | 0.01% | +250.0% |
| Q3 2019 | $104,700 | -42.4% | 14,016 | 0.0% | 0.00% | -33.3% |
| Q2 2019 | $181,928 | +6.6% | 14,016 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $170,715 | +6.9% | 14,016 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $159,642 | -47.5% | 14,016 | 0.0% | 0.00% | -40.0% |
| Q3 2018 | $304,147 | -99.9% | 14,016 | 0.0% | 0.01% | +25.0% |
| Q2 2018 | $247,663,000 | -16.1% | 14,016 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $295,037,000 | +153565.1% | 14,016 | +5.8% | 0.00% | +33.3% |
| Q4 2017 | $192,000 | -51.6% | 13,250 | -47.3% | 0.00% | +50.0% |
| Q3 2017 | $397,000 | +26.8% | 25,164 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $313,000 | -23.5% | 25,164 | 0.0% | 0.00% | -33.3% |
| Q1 2017 | $409,000 | +7.6% | 25,164 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $380,000 | -0.8% | 25,164 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $383,000 | -60.8% | 25,164 | 0.0% | 0.00% | -57.1% |
| Q2 2016 | $977,000 | +88.2% | 25,164 | +34.8% | 0.01% | +75.0% |
| Q1 2016 | $519,000 | -48.3% | 18,673 | 0.0% | 0.00% | -50.0% |
| Q4 2015 | $1,004,000 | +65.4% | 18,673 | +23.2% | 0.01% | +100.0% |
| Q3 2015 | $607,000 | +25.7% | 15,156 | +0.3% | 0.00% | +33.3% |
| Q2 2015 | $483,000 | +57.3% | 15,116 | -13.2% | 0.00% | +50.0% |
| Q4 2014 | $307,000 | +20.4% | 17,408 | -6.3% | 0.00% | 0.0% |
| Q3 2014 | $255,000 | -18.5% | 18,580 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $313,000 | – | 18,580 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |